… , is the mainstay first-line treatment for metastatic small-cell lung cancer. For non-… treatment
options then remain. Signalling pathways have been identified that might yield new drug …

… that small cell lung cancer … of treatment that have been used over the last few years and
tries to highlight the best available. As more than 50% of patients diagnosed with lung cancer are …

… Lung cancer is the first cause of cancer death worldwide [1]. Small cell lung cancer (SCLC)
accounts for 15–20% of all lung cancers and it is the most aggressive lung-cancer subtype: …

… Important advancements in the treatment of non-small cell lung cancer (… The use of small
molecule tyrosine kinase inhibitors and … Therefore, continued research into new drugs and …

… International Association for the Study of Lung Cancer (IASLC) demonstrated that patients
… 7 th edition for non-small cell lung cancer (NSCLC) (7) should be used for SCLC, since it is …

… Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase
II … The European Organization for Research and Treatment of Cancer Early Clinical Studies …

… include the use of imatinib in the treatment of c… cancers,[60] gefitinib and erlotinib in the
treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer…

… Small cell lung cancer (SCLC) is an extremely aggressive tumour type which accounts for
about 15% of lung cancer … for nonsmall cell lung cancer (NSCLC), and edition 8 uses tumour …

… 2010 for the MeSH terms “small cell lung carcinoma” or “carcinoma, small cell”. Search limits
… In November 2010, ClinicalTrials.gov was searched using the term “small cell lung cancer” …

… drugs have been approved for the treatment … drugs used to treat this cancer subtype. We
evaluated the pattern of price changes for multiple brand-name medications used for treatment …